CN109475529B - 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途 - Google Patents

氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途 Download PDF

Info

Publication number
CN109475529B
CN109475529B CN201780030906.XA CN201780030906A CN109475529B CN 109475529 B CN109475529 B CN 109475529B CN 201780030906 A CN201780030906 A CN 201780030906A CN 109475529 B CN109475529 B CN 109475529B
Authority
CN
China
Prior art keywords
fibromyalgia
formula
pain
use according
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780030906.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109475529A (zh
Inventor
曹民宰
李翰柱
黄善宽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN109475529A publication Critical patent/CN109475529A/zh
Application granted granted Critical
Publication of CN109475529B publication Critical patent/CN109475529B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780030906.XA 2016-05-19 2017-05-18 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途 Active CN109475529B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
CN109475529A CN109475529A (zh) 2019-03-15
CN109475529B true CN109475529B (zh) 2022-02-22

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780030906.XA Active CN109475529B (zh) 2016-05-19 2017-05-18 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途

Country Status (14)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
CA (1) CA3024286A1 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086076B2 (ja) * 2016-12-14 2022-06-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用
KR102739580B1 (ko) * 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
AU2019361856B2 (en) * 2018-10-19 2024-11-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
US20230000763A1 (en) * 2019-11-22 2023-01-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物
CN102574821A (zh) * 2009-10-15 2012-07-11 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法
CN102803233A (zh) * 2009-06-22 2012-11-28 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
IL159846A0 (en) * 2001-07-16 2004-06-20 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228138A (zh) * 2005-04-22 2008-07-23 Sk株式会社 神经治疗吡咯化合物
CN102803233A (zh) * 2009-06-22 2012-11-28 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法
CN102574821A (zh) * 2009-10-15 2012-07-11 爱思开生物制药株式会社 制备氨基甲酸(r)-1-芳基-2-四唑基-乙酯的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chapter 33：Fibromyalgia;JANICE E. SUMPTON等;《Handbook of Clinical Neurology》;20140101;第119卷;第513-527页 *
Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development;Gaetano Zaccara等;《Pharmacological Research》;20151212;第104卷;第38-48页 *
Meir Bialer等.Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X).《Epilepsy Research》.2010,第92卷第89-124页. *
Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI);Bialer, Meir等;《EPILEPSY RESEARCH》;20130630;第103卷(第1期);第2-30页 *
Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X);Meir Bialer等;《Epilepsy Research》;20101201;第92卷;第89-124页 *

Also Published As

Publication number Publication date
KR20170131242A (ko) 2017-11-29
EP3459543A4 (en) 2020-01-15
AU2017265839A1 (en) 2018-12-13
EP3459543A1 (en) 2019-03-27
JP7071287B2 (ja) 2022-05-18
AU2017265839B2 (en) 2022-10-27
MX2018014080A (es) 2019-04-04
US20190298694A1 (en) 2019-10-03
BR112018073553A2 (pt) 2019-03-19
US10849882B2 (en) 2020-12-01
RU2018144785A (ru) 2020-06-19
JP2019516707A (ja) 2019-06-20
WO2017200318A1 (ko) 2017-11-23
RU2753525C2 (ru) 2021-08-17
PL3459543T3 (pl) 2023-04-11
RU2018144785A3 (enExample) 2020-08-11
ES2935596T3 (es) 2023-03-08
MX394245B (es) 2025-03-19
CN109475529A (zh) 2019-03-15
CA3024286A1 (en) 2017-11-23
DK3459543T3 (da) 2023-02-13
KR102489052B1 (ko) 2023-01-16
EP3459543B1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
CN109475529B (zh) 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途
US8642661B2 (en) Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US20170035716A1 (en) Method of using solabegron
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
EP3459542B1 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
EP3854391A1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
JP2022505172A (ja) カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用
EP3711757B1 (en) Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
KR102900177B1 (ko) 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
BR112018073556B1 (pt) Uso de um composto de carbamato

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005640

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant